Somatostatin analogs: does pharmacology impact antitumor efficacy?

Chalabi, Mounira; Duluc, Camille; Caron, Philippe; Vezzosi, Delphine; Guillermet-Guibert, Julie; Pyronnet, Stéphane; Bousquet, Corinne

doi:10.1016/j.tem.2013.11.003

Cited by 58 publications

(62 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SST receptor 1-5 are responsible for activation of protein tyrosine phosphatases (PTP) which via various downstream pathways as described by Chalabi et al [17] ''ERK1/2, phosphoinositide 3-kinase (PI3 K), AKT, nitric oxide synthase (NOS), and cGMP-dependent protein kinase'' results in induction of a cyclin-dependent kinase inhibitor [18]. End result of this cascade results in pro-apoptosis, inhibition of cell migration, and arrest of cell cycle.…”

Section: Discussionmentioning

confidence: 99%

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin analogs: A Case Series

Chauhan

Ramirez

2015

Lung

View full text Add to dashboard Cite

From our single institution review of neuroendocrine pulmonary tumor cases, we found only five cases of DIPNECH, which reaffirms rare nature of the pathology. It primarily affects females over 60 years with dry cough as the most common presenting symptom. Most of our patients responded to treatment with a somatostatin analog and had significant improvement in their presenting symptoms. Somatostatin analogs were well tolerated resulting in significant resolution of presenting symptoms in most of our patients. Further research is needed; however, a trial of somatostatin analogs should be considered in the treatment of patients with DIPNECH with responders being treated long term.

show abstract

Section: Discussionmentioning

confidence: 99%

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin analogs: A Case Series

Chauhan

Ramirez

2015

Lung

View full text Add to dashboard Cite

show abstract

“…Also as a secondary effect, somatostatin analogues, like VEGF inhibitors, also affect tumor vascularization; this may be of special importance due to the highly vascular nature of the pituicytoma itself . As pituicytoma samples in our study stained mainly for SSTR 3 and 5, the use of, for example, pasireotide with a high affinity to those receptors may be a potential option . This agent has so far been approved for the use as a second line treatment in Cushing's disease and acromegaly and shown good clinical results including tumor mass reduction,…”

Section: Discussionmentioning

confidence: 74%

“…Two methodologically different treatment alternatives exist in this sector. Somatostatin receptor analogues are ligands to the receptor inducing cell cycle arrest and a downregulation of protein biosynthesis therefore creating an imbalance toward increased apoptosis within the affected stroma . Also as a secondary effect, somatostatin analogues, like VEGF inhibitors, also affect tumor vascularization; this may be of special importance due to the highly vascular nature of the pituicytoma itself .…”

Section: Discussionmentioning

confidence: 99%

Pituicytoma—An outlook on possible targeted therapies

Mende¹,

Matschke²,

Burkhardt³

et al. 2017

CNS Neurosci Ther

View full text Add to dashboard Cite

show abstract

“…The signaling pathways used by these receptors are tightly controlled, highly specific, and are complicated by networking with many other molecules. Because somatostatin analogs have recently been shown to improve progression-free survival and control symptoms related to hypersecretion, they became a first-line therapy [5] .…”

Section: Net Therapeutic Targetsmentioning

confidence: 99%

Other Novel Therapies: Biomarkers, microRNAs and microRNA Inhibitors, DNA Methylation, Epigenetics, Immunotherapy and Virotherapy

Giandomenico

Thirlwell²,

Essand³

2015

Neuroendocrine Tumors: A Multidisciplinary Approach

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) consist of heterogeneous neoplasms. The neuroendocrine cells of the human body are confined to certain organs, such as the thyroid, pancreas and adrenals, or they are dispersed throughout the body in the respiratory tract and in the intestinal mucosa. The cells belong to the diffuse endocrine cell system, share a neuroendocrine phenotype, and accumulate precursor molecules which are then processed into hormones, peptides or amines. The tightly controlled release on stimulation is either to the blood stream or adjacent cells or neurons. Neuroendocrine cells regulate various processes in the human body, such as gastrointestinal secretion, blood pressure and response to stress. NETs present a wide spectrum of malignant diseases from rather benign to very malignant and lethal variants. NETs may occur in any organ, but are mainly detected in the gastroenteropancreatic system and in the lungs. The understanding of NET biology and treatments has changed dramatically during the last decade. Today, the main problems that clinicians and translational scientists face in overcoming these malignancies relate to various aspects within the molecular pathogenesis of NETs. This chapter focuses on the importance of novel biomarkers: microRNA and microRNA inhibitors; DNA methylation and epigenetics, and immunotherapy and virotherapy to develop novel treatments for NETs.

show abstract

Somatostatin analogs: does pharmacology impact antitumor efficacy?

Cited by 58 publications

References 108 publications

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin analogs: A Case Series

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin analogs: A Case Series

Pituicytoma—An outlook on possible targeted therapies

Other Novel Therapies: Biomarkers, microRNAs and microRNA Inhibitors, DNA Methylation, Epigenetics, Immunotherapy and Virotherapy

Contact Info

Product

Resources

About